Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin

The Forkhead Box transcription factor FoxM1 regulates expression of genes that promote cell cycle progression, and it plays essential roles in the development of liver, lung, prostate and colorectal tumors. Thiazolidinediones (TZDs) activate the peroxisome proliferator-activated receptor gamma (PPARγ), a ligand-activated nuclear receptor transcription factor. We found that treatment of the human hepatoma cell lines HepG2 and PLC/PRF/5 cells with TZDs leads to inhibition of FoxM1 gene expression. No PPARγ/retinoid X receptor (RXR) consensus DNA binding sites were detected in the FoxM1 promoter extending to -10 kb upstream, and knockdown of PPARγ had no impact on TZD mediated downregulation of FoxM1 expression. Previously, others showed that PPARγ agonists inhibit the expression and DNA-binding activity of the Sp1 transcription factor. Here we show that Sp1 binds to the FoxM1 promoter region and positively regulates FoxM1 transcription, while mithramycin, a chemotherapy drug that specifically binds GC rich sequences in the DNA and inhibits activities of Sp1, inhibits expression of FoxM1. Our data suggest that TZD mediated suppression of Sp1 is responsible for downregulation of FoxM1 gene expression. Inhibition of FoxM1 expression by TZDs provides a new mechanism for TZD mediated negative regulation of cancer cell growth. FoxM1 expression and activity in cancer cells can be targeted using PPARγ agonists or the anti-neoplastic antibiotic mithramycin.

[1]  M. Maa,et al.  Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. , 2010, Chemico-biological interactions.

[2]  A. Barsotti,et al.  Pro-proliferative FoxM1 is a target of p53-mediated repression , 2009, Oncogene.

[3]  A. Gartel,et al.  p53 negatively regulates expression of FoxM1 , 2009, Cell cycle.

[4]  N. Hay,et al.  FoxM1, a critical regulator of oxidative stress during oncogenesis , 2009, The EMBO journal.

[5]  J. Asara,et al.  A Conserved Phosphorylation Site within the Forkhead Domain of FoxM1B Is Required for Its Activation by Cyclin-CDK1* , 2009, The Journal of Biological Chemistry.

[6]  A. Gartel,et al.  A novel mode of FoxM1 regulation: Positive auto-regulatory loop , 2009, Cell cycle.

[7]  A. Gartel,et al.  Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells , 2009, PloS one.

[8]  Su-Lin Lee,et al.  PPARgamma-independent antitumor effects of thiazolidinediones. , 2009, Cancer letters.

[9]  Sridhar Hannenhalli,et al.  The evolution of Fox genes and their role in development and disease , 2009, Nature Reviews Genetics.

[10]  F. Ondrey,et al.  Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention , 2009, Clinical Cancer Research.

[11]  B. Necela,et al.  Peroxisome Proliferator-activated Receptor γ Down-regulates Follistatin in Intestinal Epithelial Cells through SP1* , 2008, Journal of Biological Chemistry.

[12]  A. Tyner,et al.  FoxM1 Regulates Transcription of JNK1 to Promote the G1/S Transition and Tumor Cell Invasiveness* , 2008, Journal of Biological Chemistry.

[13]  I. Wierstra,et al.  Sp1: emerging roles--beyond constitutive activation of TATA-less housekeeping genes. , 2008, Biochemical and biophysical research communications.

[14]  M. Tretiakova,et al.  Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors , 2008, Oncogene.

[15]  B. Woda,et al.  Sp1, a New Biomarker That Identifies a Subset of Aggressive Pancreatic Ductal Adenocarcinoma , 2008, Cancer Epidemiology Biomarkers & Prevention.

[16]  W. Hung,et al.  Overexpression of Jab1 in Hepatocellular Carcinoma and Its Inhibition by Peroxisome Proliferator-Activated Receptorγ Ligands In vitro and In vivo , 2008, Clinical Cancer Research.

[17]  Jun Zhang,et al.  Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. , 2008, International journal of oncology.

[18]  J. Roman.  Peroxisome Proliferator-Activated Receptor &ggr; and Lung Cancer Biology: Implications for Therapy , 2008, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[19]  A. Tyner,et al.  FoxM1 Regulates Growth Factor-induced Expression of Kinase-interacting Stathmin (KIS) to Promote Cell Cycle Progression* , 2008, Journal of Biological Chemistry.

[20]  Ole Winther,et al.  JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update , 2007, Nucleic Acids Res..

[21]  A. Gartel.  FoxM1 inhibitors as potential anticancer drugs. , 2008, Expert opinion on therapeutic targets.

[22]  Huamin Wang,et al.  Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer , 2007, Cancer.

[23]  I. Wierstra,et al.  FOXM1, a typical proliferation-associated transcription factor , 2007, Biological chemistry.

[24]  Jun Zhang,et al.  Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. , 2007, Cancer research.

[25]  C. Chen,et al.  Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. , 2007, Cancer research.

[26]  N. Davidson,et al.  The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. , 2007, Gastroenterology.

[27]  G. Adami,et al.  Future roles for FoxM1 inhibitors in cancer treatments. , 2007, Future oncology.

[28]  René H Medema,et al.  FoxM1: at the crossroads of ageing and cancer. , 2007, Biochimica et biophysica acta.

[29]  A. Scheen.  Pharmacokinetic Interactions with Thiazolidinediones , 2007, Clinical pharmacokinetics.

[30]  Tae-Jin Lee,et al.  Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites , 2006, Molecular Cancer Therapeutics.

[31]  J. Blaydes,et al.  GC-selective DNA-binding antibiotic, Mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis , 2006, Oncogene.

[32]  C.-S. Chen,et al.  Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. , 2006, Endocrine-related cancer.

[33]  Aklank Jain,et al.  Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy , 2006, Nucleic acids research.

[34]  M. Tretiakova,et al.  The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. , 2006, Cancer research.

[35]  R. Costa,et al.  Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. , 2006, Cancer research.

[36]  P. Malfertheiner,et al.  Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo , 2006, Hepatology.

[37]  Vladimir Petrovic,et al.  Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin Ligase , 2005, Molecular and Cellular Biology.

[38]  Bingya Liu,et al.  Transcription factor Sp1 expression in gastric cancer and its relationship to long-term prognosis. , 2005, World journal of gastroenterology.

[39]  R. Costa.  FoxM1 dances with mitosis , 2005, Nature Cell Biology.

[40]  A. Gartel,et al.  The PPAR-? Agonist Pioglitazone Post-Trancriptionally Induces p21 in PC3 Prostate Cancer but Not in Other Cell Lines , 2005, Cell cycle.

[41]  C. Pilarsky,et al.  Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. , 2004, Neoplasia.

[42]  Lance D. Miller,et al.  BEARR: Batch Extraction and Analysis of cis-Regulatory Regions , 2004, Nucleic Acids Res..

[43]  Tsung-Teh Wu,et al.  Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression, Advanced Stage, and Poor Survival in Patients with Resected Gastric Cancer , 2004, Clinical Cancer Research.

[44]  Robert H. Costa,et al.  Forkhead Box M1B Transcriptional Activity Requires Binding of Cdk-Cyclin Complexes for Phosphorylation-Dependent Recruitment of p300/CBP Coactivators , 2004, Molecular and Cellular Biology.

[45]  A. Datta,et al.  Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. , 2004, Genes & development.

[46]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.

[47]  J. Ajani,et al.  Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  M. Harada,et al.  Troglitazone induces p27Kip1‐associated cell‐cycle arrest through down‐regulating Skp2 in human hepatoma cells , 2003, Hepatology.

[49]  J. Sahi,et al.  Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[50]  S. Baek,et al.  Troglitazone, a Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Selectively Induces the Early Growth Response-1 Gene Independently of PPARγ , 2003, The Journal of Biological Chemistry.

[51]  B. Song,et al.  Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. , 2003, Molecular pharmacology.

[52]  S. Baek,et al.  Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. , 2003, The Journal of biological chemistry.

[53]  T. Okumura,et al.  Troglitazone Induces G1 Arrest by p27Kip1 Induction That Is Mediated by Inhibition of Proteasome in Human Gastric Cancer Cells , 2002, Japanese journal of cancer research : Gann.

[54]  P. Farnham,et al.  Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. , 2002, Methods.

[55]  W. Hsueh,et al.  Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. , 2001, Biochemical and biophysical research communications.

[56]  A. Werner,et al.  A Review of Rosiglitazone in Type 2 Diabetes Mellitus , 2001, Pharmacotherapy.

[57]  J. Black,et al.  Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.

[58]  T. Kawaguchi,et al.  Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone‐induced cell‐cycle arrest in human hepatoma cell lines , 2001 .

[59]  T. Kawaguchi,et al.  Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. , 2001, Hepatology.

[60]  T. Okura,et al.  Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. , 2000, European journal of pharmacology.

[61]  R. Costa,et al.  Premature Expression of the Winged Helix Transcription Factor HFH-11B in Regenerating Mouse Liver Accelerates Hepatocyte Entry into S Phase , 1999, Molecular and Cellular Biology.

[62]  M. Henriksson,et al.  Interaction of the fork head domain transcription factor MPP2 with the human papilloma virus 16 E7 protein: enhancement of transformation and transactivation , 1999, Oncogene.

[63]  E. Randinitis,et al.  Clinical Pharmacokinetics of Troglitazone , 1999, Clinical pharmacokinetics.

[64]  J. Lehmann,et al.  The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. , 1999, Recent progress in hormone research.

[65]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[66]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[67]  H. Clevers,et al.  The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization. , 1997, Genomics.

[68]  H. Clevers,et al.  The winged-helix transcription factor Trident is expressed in cycling cells. , 1997, Nucleic acids research.

[69]  L. Lim,et al.  Hepatocyte Nuclear Factor 3 / fork head Homolog 11 Is Expressed in Proliferating Epithelial and Mesenchymal Cells of Embryonic and Adult Tissues , 1996 .

[70]  Eric F. Johnson,et al.  Novel Sequence Determinants in Peroxisome Proliferator Signaling (*) , 1995, The Journal of Biological Chemistry.

[71]  R. Snyder,et al.  Triplex formation prevents Sp1 binding to the dihydrofolate reductase promoter. , 1992, The Journal of biological chemistry.